May 7, 2020
Alexion will buy Portola Pharmaceuticals for $1.44B, the latest deal aimed at expanding its business beyond Soliris. Alexion is betting it can increase sales of Portola’s […]
May 14, 2020
Atul Gawande is in advanced discussions to step down as chief executive and take on a less operational role as chairman of Haven, the health-care venture […]
May 22, 2020
Private biopharma investment and fundraising has seemed unaffected by the global pandemic. US venture funding for the sector reached $5.5B in the first three months of […]
May 29, 2020
FiercePharma ranks the top 10 drug launches since 2017 by sales for their first four full quarters on the market. Drugs approved toward the end of […]
May 29, 2020
The FDA named 28 coronavirus antibody diagnostics it says should be taken off the market weeks after closing its open-door policy on COVID-19 blood tests and […]
May 29, 2020
Once valued at $4B, an embattled Akorn — nursing a market cap of roughly $37M — files for bankruptcy
Specialty generic drugmaker Akorn is filing for Chapter 11 weeks after giving up on finding itself a buyer amidst the Covid-19 pandemic. In the past few […]
June 12, 2020
Scientists, drugmakers and governments are moving with unprecedented speed to deliver a coronavirus vaccine in hopes of delivering one by the end of the year or […]
July 3, 2020
Amid escalating concerns over antibiotic resistance, several big drug makers are creating a new $1 billion for-profit venture to acquire or invest in small antibiotic companies […]
July 10, 2020
FiercePharma‘s list of highest-paid biopharma CEOs includes both midsized companies and some of the industry’s largest drugmakers. U.S. companies dominated the list, and CEOs at midsize […]